Gilead's Darusentan Posts Positive Phase III Data, Puts On Blockbuster Path
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead’s darusentan, a novel drug candidate for resistant hypertension, is on its way to becoming a likely cardiovascular blockbuster after especially positive Phase III results were released April 2.
You may also be interested in...
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.